Correlation between IDH, ATRX, and TERT promoter mutations in glioma

Shigeo Ohba,Kiyonori Kuwahara,Seiji Yamada,Masato Abe,Yuichi Hirose

DOI: https://doi.org/10.1007/s10014-020-00360-4

2020-03-29

Brain Tumor Pathology

Abstract:According to the 2016 World Health Organization (WHO) classification of central nervous system tumors, diffuse astrocytic and oligodendroglial tumors are differentiated by the presence of <i>isocitrate dehydrogenase 1 or 2</i> (<i>IDH1/2</i>) mutation and the combined loss of the short arm of chromosome 1 and the long arm of chromosome 19 (1p/19q co-deletion). <i>IDH</i>-mutant astrocytoma often has <i>p53</i> and <i>alpha-thalassemia/mental retardation syndrome X-linked</i> (<i>ATRX</i>) mutation, showing the alternative lengthening of telomeres (ALT) phenotype, while <i>IDH</i>-mutant and 1p/19q-co-deleted oligodendroglioma often have wild-type <i>p53</i> and <i>telomerase reverse transcriptase</i> (<i>TERT</i>) promoter mutation, showing telomerase activation. This study analyzed <i>IDH</i>, <i>ATRX</i>, and <i>TERT</i> promoter mutations, and the correlation between them. Immortalized cells overcome the telomere-related crisis by activating telomerase or ALT. In glioma, telomerase is mainly activated by <i>TERT</i> promoter mutation, while ALT is usually associated with <i>ATRX</i> mutation. Although the mechanism of how <i>ATRX</i> mutation induces ALT remains unclear, ATRX loss alone is believed to be insufficient to induce ALT. Treatments targeting telomere maintenance are promising.

oncology,pathology,clinical neurology